Lundbeck has FDA Fast Track status for Lu AH69593, but can it catch the narcolepsy orexin leaders?
Lundbeck’s Lu AH69593 gains FDA Fast Track status, but its Phase 1 narcolepsy programme enters an increasingly competitive orexin field.
Pharma & Biotech
Pharma & Biotech
Alkermes’ alixorexton improves narcolepsy type 2 symptoms as Phase 3 risk comes into focus
Discover how Alkermes’ alixorexton could reshape narcolepsy type 2 treatment as Phase 3 tests its efficacy, dosing and long-term safety.